8-K: Geron's Imetelstat Receives Positive Vote from FDA Advisory Committee for Anemia Treatment

The FDA's Oncologic Drugs Advisory Committee voted 12 to 2 in favor of Geron's imetelstat for treating transfusion-dependent anemia in lower-risk MDS patients.

Summary

• Geron Corporation announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for treating transfusion-dependent anemia in adult patients with lower-risk myelodysplastic syndromes (LR-MDS).
• The positive vote was based on results from the IMerge Phase 3 clinical trial, which showed a statistically significant improvement in red blood cell transfusion independence (RBC-TI) with imetelstat compared to placebo.
• Specifically, the primary endpoint of at least 8-week RBC-TI was significantly higher with imetelstat, and 28% of imetelstat-treated patients achieved at least 24-week RBC-TI compared to 3% on placebo.
• The median duration of RBC-TI approached one year for imetelstat 8-week responders and was 80 weeks for those achieving 24-week RBC-TI.
• The most common Grade 3-4 adverse events were thrombocytopenia (62%) and neutropenia (68%), which were generally manageable and of short duration.
• The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024, for the imetelstat New Drug Application (NDA).

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment due to the favorable ODAC vote and strong clinical trial results. However, there are still risks associated with regulatory approval and commercialization, preventing a perfect score.

Positives

• The positive ODAC vote significantly increases the likelihood of FDA approval for imetelstat.
• The IMerge Phase 3 trial demonstrated a clear benefit for patients with transfusion-dependent anemia in lower-risk MDS.
• Imetelstat showed clinically meaningful RBC-TI across key MDS subgroups.
• A sustained increase in mean hemoglobin levels was observed in imetelstat-treated patients compared to placebo.
• The adverse events were generally manageable and of short duration.

Negatives

• The most common Grade 3-4 adverse events were thrombocytopenia (62%) and neutropenia (68%).
• Imetelstat is not yet approved by any regulatory authority.

Risks

• There are risks and uncertainties related to regulatory approval, including potential delays or the need for additional clinical trials.
• There are risks related to manufacturing and supplying sufficient quantities of imetelstat.
• The actual timing for the interim and final analyses of the IMpactMF trial may vary.
• There is a risk that future safety or efficacy results could cause the benefit-risk profile of imetelstat to become unacceptable.
• Geron may need to raise substantial additional capital to complete the development and commercialization of imetelstat.

Future Outlook

Geron plans to commercially launch imetelstat in the U.S. upon potential FDA approval, and the European Medicines Agency (EMA) is also reviewing the Marketing Authorization Application (MAA) for the same indication. Geron also has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis.

Management Comments

• We are pleased with the Committee's decision to recognize the positive clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS, said Faye Feller, M.D., Geron's Executive Vice President, Chief Medical Officer.
• We believe that imetelstat has the potential to be an important new medicine for patients and look forward to continuing our collaboration with the FDA as they complete their review of our New Drug Application.

Industry Context

This announcement is significant as it represents a potential new treatment option for patients with lower-risk MDS who have limited treatment options. The positive ODAC vote suggests a strong likelihood of FDA approval, which could position Geron as a key player in the hematologic malignancies market.

Comparison to Industry Standards

• The 28% 24-week RBC-TI rate for imetelstat is a significant improvement compared to the 3% rate observed in the placebo group, and is a clinically meaningful result in the context of current treatment options for this patient population.
• Current treatments for lower-risk MDS often involve erythropoiesis-stimulating agents (ESAs), which many patients become resistant to or are ineligible for, highlighting the unmet need that imetelstat aims to address.
• While specific competitor data is not provided in this document, the results suggest that imetelstat could offer a more effective treatment option for transfusion-dependent anemia in lower-risk MDS compared to existing therapies.

Stakeholder Impact

• Shareholders are likely to react positively to the news of the favorable ODAC vote.
• Patients with transfusion-dependent anemia in lower-risk MDS may have a new treatment option available.
• Employees of Geron may be positively impacted by the potential commercial success of imetelstat.

Next Steps

• Geron will continue to work with the FDA as they complete their review of the New Drug Application.
• Geron plans to commercially launch imetelstat in the U.S. upon potential FDA approval.
• The European Medicines Agency (EMA) is also reviewing the Marketing Authorization Application (MAA) for the same indication.
• Geron will continue the ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis.

Key Dates

Keywords

Imetelstat, Myelodysplastic Syndromes, MDS, Transfusion-Dependent Anemia, FDA, ODAC, Oncologic Drugs Advisory Committee, RBC-TI, IMerge Phase 3, Hematologic Malignancies, Telomerase Inhibitor